The shareholders of APIM Therapeutics and Nordic Nanovector ASA, a listed Norwegian biotechnology company (OSE: NANOV), have announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing a portfolio of clinical and preclinical oncology programs including multiple clinical studies for its lead candidate ATX-101. For more information about the merger agreement, please read the corresponding press release.
